Worachart SirawarapornRachada SirawarapornAtid ChanpongsriWilliam R. JacobsDaniel V. SantiMahidol UniversityUniversity of California, San FranciscoAlbert Einstein College of Medicine of Yeshiva University2018-08-102018-08-101991-01-01Experimental Parasitology. Vol.72, No.2 (1991), 184-19010902449001448942-s2.0-0026113224https://repository.li.mahidol.ac.th/handle/20.500.14594/22061Dihydrofolate reductase (DHFR) from extracts of Mycobacterium smegmatis strain mc26 and trimethoprim-resistant mutant mc226 was purified to homogeneity. In crude extracts, the specific activity of the enzyme from the trimethoprim resistant strain was comparable to that from the sensitive strain. The DHFR from both sources was purified using affinity chromatography on MTX-Sepharose followed by Mono Q FPLC. The enzyme has an apparent molecular mass of 23 kDa from gel filtration on Sephadex G-100 and from SDS-PAGE. Amino terminal sequence analysis showed homology with DHFRs from a subset of other gram-positive organisms. The purified enzyme from the trimethoprim-sensitive organism exhibited Kmvalues for H2folate and NADPH of 0.68 ± 0.2 μM and 21 ± 4 μM, respectively. The Kmvalues for H2folate and NADPH for the enzyme from the drug-resistant organism were 1.8 ± 0.4 μM and 5.3 ± 1.5 μM, respectively. A Kcatof 4.5 sec-1was determined for the DHFR from both sources. The enzyme from both sources was competitively inhibited by pyrimethamine and trimethoprim. The Kivalue of trimethoprim, for the enzyme from the drug-resistant organism was about six-fold higher than for the enzyme from drug-sensitive strain. Our data suggest that mutation of DHFR contributes to trimethoprim resistance in the mc226 strain of M. smegmatis. © 1991.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1016/0014-4894(91)90136-K